DigestRedComo funciona
Red
/
Empresas
Bo
No verificado

Boehringer Ingelheim Limited

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

32 Comunicados de prensa

Ver todos los comunicados de prensa
28/11/2025
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim announces appointment to Board of Managing Directors
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
04/11/2025
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
29/10/2025
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
22/10/2025
Farmacéutica
Medicina Salud Bienestar
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
17/10/2025
Farmacéutica
Medicina Salud Bienestar
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
15/10/2025
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
09/10/2025
Farmacéutica
Medicina Salud Bienestar
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
28/09/2025
Farmacéutica
Medicina Salud Bienestar
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
01/09/2025
Farmacéutica
Medicina Salud Bienestar
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
18/08/2025
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0